Patient adherence to allergic rhinitis treatment: Results from patient surveys

MedGenMed Medscape General Medicine

Volumn 10, Issue 10, 2008, Pages

  Valovirta, Erkka ^a   Ryan, Dermot ^b,c  

^a Turku Allergy Center   (Finland)

^b Woodbrook Medical Centre   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID;

ALLERGIC RHINITIS; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMOTION; HEALTH SURVEY; HUMAN; MONOTHERAPY; NOSE CONGESTION; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW; SINUS CONGESTION; SLEEP DISORDER; SYMPTOM; UNSPECIFIED SIDE EFFECT; HAY FEVER; INTERNATIONAL COOPERATION; META ANALYSIS; PATIENT; STATISTICS; TREATMENT OUTCOME;

HEALTH SURVEYS; HUMANS; INTERNATIONALITY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PATIENTS; QUALITY OF LIFE; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 56149124147     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Scadding GK, Durham SR, Mirakian R, et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy. 2008;38:19-42.
2. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
3. Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108:S2-S8.
4. Demoly P, Allaert F-A, Lecasble M, PRAGMA. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy. 2002;57:546-554.
5. Vuurman EFPM, van Veggel LMA, Uiterwijk MMC, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993;71:121-126.
6. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
7. The UCB Institute of Allergy: European Allergy White Paper. Chapter 5. Socio-economic costs of allergic diseases. Available at: http://www.theucbinstituteofallergy.com/ioalmages/247_13_CH_5_tcm75- 5864.pdf Accessed June 7, 2007.
8. American Academy of Allergy Asthma & Immunology. The Allergy Report, Volume II: Diseases of the atopic diathesis. Available at: http://www.aaaai.org/ar/volume2.pdf Accessed November 2, 2007.
9. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med. 2000;162:1391-1396.
10. Scadding GK, Richards DH, Price MJ. Patient and physician perspectives on the impact and management of perennial and seasonal allergic rhinitis. Clin Otolaryngol. 2000;25:551-557.
11. Lamb CE, Ratner PH, Johnson CE, et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin. 2006;22:1203-1210.
12. Demoly P, Crampette L, Daures JP. National survey on the management of rhinopathies in asthma patients by French pulmonologists in everyday practice. Allergy. 2003;58:233-238.
13. Bousquet J, van Cauwenberge P, Khaltaev N, and the Workshop Expert Panel. Allergic Rhinitis and its Impact on Asthma (ARIA) in collaboration with the World Health Organization. Executive summary of the Workshop Report. Allergy. 2002;57:841-855.
14. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116-134.
15. Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf. 2003;26:863-893.
16. Allen DB. Do intranasal corticosteroids affect childhood growth? Allergy. 2000;55(suppl 62):15-18.
17. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2004;93:61-67.
18. Patel P, Ratner P, Clements D, Wu W, Philpot E. Twenty-four serum and urine cortisol data support hypothalamic-pituitary-adrenocortical axis safety of once-daily fluticasone furoate nasal spray 110 mcg in adolescents and adults with perennial allergic rhinitis. Allergy. 2007;62(suppl 83):226.
19. Gradman J, Caldwell M, Wolthers O. Comparison of short term lower leg growth in children treated with fluticasone furoate nasal spray and vehicle placebo spray. Allergy. 2007;62(suppl 83):226-227.
20. Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30:317-326.
21. Meltzer EO. Intranasal steroids: managing allergic rhinitis and tailoring treatment to patient preference. Allergy Asthma Proc. 2005;26:445-451.
22. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. Available at: http://www.myallergiesinamerica.com Accessed June 7, 2007.
23. Forbes Consulting Group. Understanding the Dynamics Surrounding Allergy Suffering and Treatment. Lexington, MA; 2005.
24. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Respir Med. 2005;4:439-446.
25. Long AA. Findings from a 1000-patient Internet-based survey assessing the impact of morning symptoms on individuals with allergic rhinitis. Clin Ther. 2007;29:342-351.
26. Synovate. Nasonex Claims Evaluation Final Report. December 2006.
27. Roper Public Affairs and Media. Impact of Nasal Congestion Among Allergic Rhinitis Sufferers; 2004.
28. Kakumanu S, Glass C, Craig T. Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. Am J Respir Med. 2002;1:195-200.
29. Craig TJ, Teets S, Lehman EB, Chinchilli VM, Zwillich C. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol. 1998;101:633-637.
30. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120:381-387.
31. Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med. 2005;4:289-296.
32. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89:292-297.
33. Lumry W, Hampel F, LaForce C, Kiechel F, El-Akkad T, Murray JJ. A comparison of once-daily triamcinolone acetonide aqueous and twice-daily beclomethasone dipropionate aqueous nasal sprays in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc. 2003;24:203-210.
34. Stokes M, Amorosi SL, Thompson D, Dupclay L, Garcia J, Georges G. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg. 2004;131:225-231.
35. Dykewicz MS, Fineman S. Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998;81:463-468.
36. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: a systematic review of randomized controlled trials. BMJ. 1998;317:1624-1629.
37. Yáñez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol. 2002;89:479-484.
38. Barnes ML, Ward JH, Fardon TC, Lipworth BJ. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy. 2006;36:676-684.
39. Nielson LP, Mygind N, Dahl R. Intranasal corticosteroids for allergic rhinitis: superior relief? Drugs. 2001;61:1563-1579.
40. Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized, placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy. 2004;34:259-267.
41. Graf P. Rhinitis medicamentosa: a review of causes and treatment. Treat Respir Med. 2005;4:21-29.
42. Hyland ME, Ståhl E. Asthma treatment needs: a comparison of patients' and health care professionals' perceptions. Clin Ther. 2004; 26:2141-2153.
43. Ryan D, Grant-Casey J, Scadding G, Pereira S, Pinnock H, Sheikh A. Management of allergic rhinitis in UK primary care: baseline audit. Prim Care Respir J. 2005;15:204-209.
44. Ryan D, van Weel C, Bousquet J, et al. Primary care: the cornerstone of diagnosis of allergic rhinitis. Allergy. 2008;63:981-989.